New imaging agent shows promise for spotting prostate cancer
NCT ID NCT03995888
First seen Feb 18, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This early-stage study tested a new radioactive imaging agent, rhPSMA-7.3 (18F), in 24 people—some healthy and some with prostate cancer. The goal was to see if it is safe and can help doctors see prostate cancer on scans. The study focused on safety and how the agent spreads through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, FI-20520, Finland
Conditions
Explore the condition pages connected to this study.